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Abstract: Purpose:   Total pancreatectomy for severe pain in end stage chronic pancreatitis may
be the only option but with vascular involvement this is usually too high risk and/or
technically not feasible. The purpose of the study was to present the clinical outcomes
of a novel procedure in severe chronic pancreatitis complicated by uncontrollable pain
and vascular involvement.
Methods:   We describe an in-situ near-total pancreatectomy that avoids peri-
pancreatic vascular dissection (Livocadoprocedure) and report on surgical and clinical
outcomes.
Results:   The Livocado procedure was carried out on 18 (3.9%) of 465 patients
undergoing surgery for chronic pancreatitis. There were 13 men and 5 women with a
median (IQR) age of 48.5 (42.4-57) years and weight of 60.7 (58.0-75.0) Kg. All had
severe pain and vascular involvement; 17 had pancreatic parenchymal calcification;
the median (IQR) oral morphine equivalent dose requirement was 86 (33-195) mg/day.
The median (IQR) maximal pain scores were 9 (9-10); the average pain score was 6
(IQR 4-7).  There was no perioperative or 90-day mortality. At a median (IQR) follow-up
of 32.5 (21-45.75) months both maximal and average pain scores were significantly
improved post-operatively, and at 12 months two-thirds of patients were completely
pain free. Six (33%) patients had employment pre-operatively versus 13 (72%) post-
operatively (p=0.01).
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Conclusions:   The Livocado procedure was safe and carried out successfully in
patients with chronic pancreatitis with vascular involvement where other procedures
would be contraindicated. Perioperative outcomes, post-operative pain scores and
employment rehabilitation were comparable with other procedures carried out in
patients without vascular involvement.
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Response to Reviewers' Comments. 
 
We appreciate the positive comments and have made changes as recommended where 
possible, highlighting the changes as well as producing a clean revised version. 
 
Reviewer #1:  
 
Responses as follows. 
 
1. We believe its important to describe in some detail the first two cases to elaborate on 
why this procedure is necessary and how it has evolved. We have also taken the 
opportunity to shorten the description of each case as suggested.  
2. We have now included a Table with details of baseline demographic, operative 
details, and outcomes. 
3. The correct formal name of Pietro Contin is now used. 
 
Reviewer #2:  
 
1. This Reviewer asks which cases were more appropriate for Livocado than for e.g. 
Bern-Büchler procedure, as the latter also avoids vascular contact in cases with 




We have however already stated in the Introduction that whilst the Duodenum- 
preserving pancreatic head resection (DPPHR) notably the Beger, Frey and Berne 
procedures are effective for head dominant disease, providing decompression of the 
duodenum, hepatic portal vein, main pancreatic duct and intra-pancreatic bile duct.19-
22” …”there remains a role for total pancreatectomy in a highly select group of 
patients with end staged CP affecting the entire pancreas,  intractable pain and pre-
existing endocrine failure.2, 23-25” Also in the “Eligibility Criteria” we state that “The 
in-situ near-total pancreatectomy procedure was only considered in a highly selected 
small subset of patients that had all of the following criteria. (1) severe end stage 
chronic pancreatitis where the whole pancreas was diseased with exocrine/endocrine 
failure; (2) daily debilitating abdominal pain unresponsive to medical treatment; (3) 
duodenum-and spleen-preserving near-total pancreatectomy or standard total 
pancreatectomy was technically not feasible, notably due to vascular and/or other 
intra-abdominal complications; (4) demonstrable abstinence from alcohol for more 
than 6 months.” 
 
The “Bern-Büchler procedure” and similar procedures targets disease in the head of 
the pancreas with drainage of functioning tissue in the uncinate and body and tail of 
the pancreas whilst the Livocado procedure aims to remove all disease parenchyma 
including the head uncinate body and tail of the pancreas. This now further explained 
in the Discussion as follows. 
 
“Whilst the duodenum-preserving pancreatic head resections such as the Beger, Berne 
and Frey procedures target disease in the head of the pancreas with drainage of 
authors' response to reviewers' comments Click here to access/download;authors' response to reviewers'
comments;Respoonse Reviewers Livocado 4 Jan 2021.docx
functioning tissue in the uncinate and body and tail of the pancreas, the Livocado 
procedure aims to remove all disease parenchyma including the head, uncinate 
process, body, and tail of the pancreas. “ 
 
“As described by  Izbicki et al “ the Hamburg modification, which involved a V-
shaped excision of the pancreatic body beyond the deep duodenum-preserving head 
resection, aiming to reach second-order and third-order pancreatic side branches. The 
concept behind this V-shaped excision was the idea of eliminating potential stenosis 
and prevention of stenosis that may appear as the disease, hypothetically resulting in 
better long- term outcomes.” 37,38 The indication is for patients with dominant head 
disease. In contrast the Livocado procedure is for patients with involvement of the 
whole gland requiring a total pancreatotomy with removal of all diseased tissue but 
leaving a posterior capsule in patients at high risk because of vascular involvement.” 
 
2. The patients had, possibly due to the extended resection, a high rate (94%) of 
postoperative diabetes mellitus. Ideally, a surgical procedure for CP should also 




The Livocado is not an “extended resection” it is near-total pancreatectomy in end stage 
endocrine and exocrine failure. Before the Livocado procedure 100% of patients had exocrine 
failure and 61% had endocrine failure. The rate of endocrine failure was not 100% because 
incipient endocrine failure is not always revealed in these patients because of restricted 
dietary intake. After the Livocado procedure as expected 100% still had exocrine failure but 
with significantly more lipase supplements required (due to increased dietary intake) and 
only one patient was not overtly diabetic – again this is anticipated because a small fraction 
of patients can adapt to this state. 
 
Reviewer #3:  
1. I still strongly object to calling it the Livocado-procedure. You might want to call it a near 
total pancreatectomy, but it is definitely not a new procedure. In the end it is a modification 
of the Frey procedure, you might want to call it a "deep Frey", but I don't think it´s useful ta 




As explained above it is a completely new procedure. 
 
Charlie Frey (who seems to have got the idea from Hand Beger on his visits to Ulm) 
described this as follows. 
 
“The operation features duodenal-preserving resection of the head of the pancreas combined 
with lon-gitudinal pancreaticojejunostomy of the body and tail of the pancreas. The operation 
has application to patients with pain or complications of chronic pancreatitis with dilated 
ducts in the body and tail of the pancreas who have small strictured ducts and/or small 
pseudocysts or ducts impacted with calculi in a markedly enlarged fibrotic pancreatic head.” 
 
As we say in response to Reviewer #2 and now add to the discussion: 
 
“The indication [of the Beger, Berne Frey, modified Hamburg procedure] is for 
patients with dominant head disease. In contrast the Livocado procedure is for 
patients with involvement of the whole gland requiring a total pancreatotomy with 
removal of all diseased tissue but leaving a posterior capsule in patients at high risk 
because of vascular involvement.” 
 
Only 44% in this series had dominant head disease whilst 94% had calcification and 
100% had vascular complications.  
 
 
2. The authors themselves compare their procedure to the Hamburg procedure, which is 
also sort of a "deep-Frey". The postoperative diabetes though is much higher (94% vs. 64%), 




We are not sure what a ‘deep-Frey” procedure is as the Hamburg group have described the 
modified Hamburg procedure in the following terms: 
 
“ the Hamburg modification, which involved a V-shaped excision of the pancreatic body 
beyond the deep duodenum-preserving head resection, aiming to reach second-order and 
third-order pancreatic side branches. The concept behind this V-shaped excision was the idea 
of eliminating potential stenosis and prevention of stenosis that may appear as the disease, 
hypothetically resulting in better long- term outcomes.” 
 
“The Hamburg modification. ( A ) Subtotal nonanatomic “coring out”type resection of the 
pancreatic head including the uncinate process and a longitudinal V-shaped excision of the 
ventral aspect of the body and the tail of the pancreas.” 
 
“Thus, the Hamburg modification of the DPPHR focuses on sustaining drainage of the 
pancreatic side branches and their junction with the main duct.” 
 
The aim in the Hamburg procedure is to preserve tissue with the aim of a functional 
improvement both exocrine and endocrine. 
 
This is inapplicable and not comparable to the patients requiring the Livocado procedure as 
there is already complete or near complete endocrine and exocrine failure 
 
According to Charlie Frey: 
 
“In our experience, about 40-50% of the patients with chronic pancreatitis requiring operation 
fulfil these criteria.” 
 
Similarly the Hamburg group have reported on 500 consecutive patients having the Hamburg 
modification – the predominate operation for chronic pancreatitis. 
 
In the current series we report the following experience: 
 
 
“Between January 1997 and May 2020 approximately 1200 patients with a diagnosis of 
chronic pancreatitis were referred to the Liverpool Pancreas Centre for further evaluation. 
Surgery was undertaken in 465 patients comprising a pylorus preserving partial pancreato-
duodenectomy in 133 (28.6%), a Beger’s duodenum head resection in 130 (28.0%), a 
classical Kausch-Whipple pancreata-duodenectomy in 8 (1.7%) patients, a left 
pancreatectomy (with or without spleen preservation) in 43 (9.3%), various drainage 
procedures in 67 (14.4%) patients (including Partington-Rochelle, Izbicki V-procedure, and 
pseudocyst-jejunostomy), and total pancreatectomy in 66 (14.2%) patients (including 
duodenum and spleen preserving near-total pancreatectomy in 51). The remaining 18 (3.9%) 
patients (13 men and 5 women) underwent a Livocado resection all with severe 
uncontrollable pain as the primary indication”. 
 
Thus the indication for total pancreatectomy was in 84 (18%) patients of those undergoing 
surgery; altogether only 18 (3.9%) patients had the Livocado procedure. 
 
Thus the advantage is that without the Livocado procedure no pancreatic surgery would have 
been undertaken in these 18 patients because the surgical risks for a standard total 
pancreatectomy were too high and it would be pointless in removing only some of the 
diseased pancreatic tissue in terms of symptom control. 
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Purpose: Total pancreatectomy for severe pain in end stage chronic pancreatitis may be the 
only option but with vascular involvement this is usually too high risk and/or technically not 
feasible. The purpose of the study was to present the clinical outcomes of a novel procedure in 
severe chronic pancreatitis complicated by uncontrollable pain and vascular involvement. 
Methods: We describe an in-situ near-total pancreatectomy that avoids peri-pancreatic 
vascular dissection (Livocado procedure) and report on surgical and clinical outcomes. 
Results: The Livocado procedure was carried out on 18 (3.9%) of 465 patients undergoing 
surgery for chronic pancreatitis. There were 13 men and 5 women with a median (IQR) age of 
48.5 (42.4-57) years and weight of 60.7 (58.0-75.0) Kg. All had severe pain and vascular 
involvement; 17 had pancreatic parenchymal calcification; the median (IQR) oral morphine 
equivalent dose requirement was 86 (33-195) mg/day. The median (IQR) maximal pain scores 
were 9 (9-10); the average pain score was 6 (IQR 4-7).  There was no perioperative or 90-day 
mortality. At a median (IQR) follow-up of 32.5 (21-45.75) months both maximal and average 
pain scores were significantly improved post-operatively, and at 12 months two-thirds of 
patients were completely pain free. Six (33%) patients had employment pre-operatively versus 
13 (72%) post-operatively (p=0.01). 
Conclusions: The Livocado procedure was safe and carried out successfully in patients with 
chronic pancreatitis with vascular involvement where other procedures would be 
contraindicated. Perioperative outcomes, post-operative pain scores and employment 






Chronic pancreatitis is a complex inflammatory syndrome of the pancreas with pain as the 
predominant symptom.1 It affects individuals with genetic, environmental and/or other risk 
factors who develop persistent pathological responses to parenchymal injury or stress.2, 3 CP is 
a major source of morbidity with the incidence and prevalence estimated to be around 5-12 per 
105 per year and 50 per 105 respectively.4-7 4-7 Chronic pancreatitis carries a heavy disease 
burden including chronic pain, pancreatic endocrine and exocrine failure leading to diabetes 
mellitus and malnutrition, lower quality of life, serious long-term complications including a 5–
25-fold risk of pancreatic cancer, and social stigma, with a reduced life expectancy.8-10 
The long-term morphological sequelae of chronic inflammation, fibrosis and loss of 
parenchymal architecture result in ductal and parenchymal calcifications, ductal strictures, 
inflammatory masses, pseudocysts, biliary and duodenal obstruction, pancreatic fistulae, and 
pancreatic ascites.2, 3, 8, 9 Vascular complications include porto-mesenteric venous compression 
or occlusion, extra-hepatic portal hypertension, splenic-portal-thrombosis, venous 
collateralization and pseudo-aneurysm.2, 11-14 Longitudinal studies show that 40-75% of CP 
patients require surgical intervention most commonly for intractable pain.15-18 Duodenum- 
preserving pancreatic head resection (DPPHR) notably the Beger, Frey and Berne procedures 
are effective for head dominant disease, providing decompression of the duodenum, hepatic 
portal vein, main pancreatic duct and intra-pancreatic bile duct.19-22  
There remains a role for total pancreatectomy in a highly select group of patients with end 
staged CP affecting the entire pancreas,  intractable pain and pre-existing endocrine failure.2, 
23-25  Total pancreatectomy in chronic pancreatitis is however associated with substantial 
morbidity and mortality especially in cases with vascular involvement. The aim of this study 
was to evaluate the early and late outcomes of a novel surgical procedure which offers an 
alternative for patients who would otherwise require a total pancreatectomy. This procedure 
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combines a duodenum preserving pancreatic head resection with extended coring of the neck, 
body and tail of the pancreas, leaving only an outer rim of fibrosed tissue, which is anastomosed 
to a Roux-en-Y jejunal limb.  
METHODS 
Study Design 
This is a single-center cohort series of consecutive patients with chronic pancreatitis referred 
to the Liverpool Pancreas Centre for further evaluation between January 1997 and May 2020. 
The in-situ near-total pancreatectomy procedure was first introduced on 30 December 2014 
and the last procedure was undertaken on 11 February 2020. The data lock for all patients was 
18 May 2020. A prospectively maintained database recorded demographic, clinical, 
radiological, genetic and histopathological data along with the patient’s performance status and 
employment status during initial patient clinical assessment in the pancreas outpatient clinic. 
All patients were asked to complete patient reported pain scores on a visual analogue scale 
scores recorded on a 10-point Likert scale (0–10), including maximal (“worst”) pain and 
average pain. Patients were followed up after discharge in accordance with local clinical 
protocol, which comprised of routine assessment at 4-6 weeks, 3, 6 and 12 months, then 
annually with additional review as clinically required. Data collected at follow-up included 
weight, diabetes status, presence of steatorrhea, pancreatic enzyme replacement dosage, 
analgesia requirements, employment status and pain scores. The equianalgesic equivalence to 
oral morphine was calculated for all opiate medications as recommended by the Royal College 
of Anaesthetists of England.26 Complications were graded according to Dindo et al.27 Data 
were censored at the point when patients were discharged, lost to follow-up or died.  
Diagnosis of Chronic Pancreatitis 
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The diagnosis of CP was based on clinical and radiological criteria and confirmed in all patients 
following histopathological assessment of operative specimens.28, 29 CP secondary to alcohol 
required alcohol consumption of ≥ 62 units per week for ≥ 1 year.30 Patients with idiopathic 
CP were classified into two groups: (1) idiopathic with no genetic background and with a 
genetic background.31 The presence of pancreatic exocrine insufficiency was based on clinical 
assessment, and the response of steatorrhea to pancreatic enzyme replacement therapy. 
Radiological Review 
Vascular assessment was made on the basis of a preoperative pancreas protocol CT including 
arterial and portal venous phase imaging. All CT scans were reviewed and scored 
retrospectively by a specialist pancreatic radiologist blinded to patient outcomes.28  
Eligibility Criteria 
The in-situ near-total pancreatectomy procedure was only considered in a highly selected small 
subset of patients that had severe end stage chronic pancreatitis where the whole pancreas was 
diseased with exocrine and endocrine insufficiency and daily debilitating abdominal pain 
unresponsive to medical treatment, and abstinence from alcohol for more than 6 months. 
Operative Description 
The duodenum and pancreas were exposed as described previously and the duodenum was 
fully Kocherized.23 The pancreatic margins were defined by dividing the superior and inferior 
peritoneal reflections and the right gastroepiploic vein (or the gastrocolic trunk of Henle when 
required) was ligated and divided to fully reflect the antrum of the stomach off the anterior 
head of the pancreas. Hemostatic sutures are placed around the entire pancreatic margin (Figure 
1A). The pancreatic head was cored out following the principles of the Berne modification of 
the Beger procedure.32 This resection was continued across the neck of the pancreas taking 
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extreme care of the superior mesenteric, hepatic portal venous axis and along the entire length 
of the body and tail of the pancreas. All pancreatic tissue anterior to the main pancreatic duct 
and as much of the tissue superior, inferior and posterior to the duct as possible was cored out 
leaving only a thin fibrotic outer rim of pancreas. Because of the dense fibrous tissue and 
calcification, a combination sharp dissection with a scalpel and scissors was required. This is 
analogous to a cored-out avocado providing the term Livocado in part reference to its origin in 
Liverpool. A cholecystectomy was then performed, and the cystic duct was catheterized using 
an umbilical feeding catheter. This tube was palpated within the cored out pancreatic head and 
the intrapancreatic bile duct was incised and widely marsupialized using 4 to 6 interrupted 4-0   
sutures (Figure 1B). The jejunum was divided using a linear cutter-stapler and the distal limb 
was delivered through an incised transverse mesocolon defect as a Roux-en-Y. The jejunal 
limb was opened by a diathermy longitudinal incision along the anti-mesenteric border and 
sutured to the pancreatic rim using continuous 4-0 PDS sutures between stays as follows. The 
distal end of the limb was first parachuted to the tip of the tail of the pancreas using interrupted 
stay sutures. The inferior pancreatic rim was then sutured to the jejunal enterotomy using a 
continuous suture and full thickness bites, across the neck and around the inferior aspect of the 
cored-out head and uncinated process. The superior border of the pancreatic rim was then 
continuously sutured to the jejunal enterotomy again from tail to head. Along the 
pancreatoduodenal groove the jejunal enterotomy could be sutured to the medial duodenal wall 
if needed. The superior and inferior sutures were then tied together when meeting (Figure 1C). 
The gastroduodenal limb was then anastomosed side-to-side to the pancreatic limb to complete 
the Roux-en-Y. 
Eligibility Criteria 
The in-situ near-total pancreatectomy procedure was only considered in a highly selected small 
subset of patients that had all of the following criteria. 
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(1) severe end stage chronic pancreatitis where the whole pancreas was diseased with 
exocrine/endocrine failure; 
(2) daily debilitating abdominal pain unresponsive to medical treatment; 
(3) duodenum-and spleen-preserving near-total pancreatectomy or standard total 
pancreatectomy was technically not feasible, notably due to vascular and/or other intra-
abdominal complications; 
(4) demonstrable abstinence from alcohol for more than 6 months.  
Statistical Analysis 
Continuous variables are presented as median and interquartile range (IQR). Statistical 
comparison was by using the Wilcoxon Rank test for paired data based on a 2-tailed alpha. 
Categorical variables are presented as frequency and percentage and were analyzed using the 
Χ2 test, or Fishers exact probability test. Significance was set at the 5% level (p < 0.05). SPSS 
v24 was used for the analyses. 
RESULTS 
Patient Demographics and Chronic Pancreatitis Characteristics 
Between January 1997 and May 2020 approximately 1200 patients with a diagnosis of chronic 
pancreatitis were referred to the Liverpool Pancreas Centre for further evaluation. Surgery was 
undertaken in 465 patients comprising a pylorus preserving partial pancreato-duodenectomy in 
133 (28.6%), a Beger’s duodenum head resection in 130 (28.0%), a classical Kausch-Whipple 
pancreata-duodenectomy in 8 (1.7%) patients, a left pancreatectomy (with or without spleen 
preservation) in 43 (9.3%), various drainage procedures in 67 (14.4%) patients (including 
Partington-Rochelle, Izbicki V-procedure, and pseudocyst-jejunostomy), and total 
pancreatectomy in 66 (14.2%) patients (including duodenum and spleen preserving near-total 
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pancreatectomy in 51). The remaining 18 (3.9%) patients (13 men and 5 women) underwent a 
Livocado resection all with severe uncontrollable pain as the primary indication, with baseline 
demographic and operative details shown in Table 1. The median (IQR) age was 48.5 (42.4-
57) years and median (IQR) weight 60.7 (58.0-75.0) Kg and a BMI 21.2 (20.1-25.5). The 
median (IQR) duration of symptoms at the time of surgery was 4 (2–10.3) years. The etiology 
was excess alcohol in 12 with a prior median (IQR) consumption of 200 (100 – 245) units per 
week. Six patients were idiopathic of whom one had a genetic background (a heterozygous 
SPINK-1 pAsn34Ser variant and a heterozygous CFTR pArg117His mutation). 17 patients had 
a history of tobacco smoking, of whom 13 were current smokers, with a median (IQR) 26.3 
(19.2-37) pack years; one patient had never smoked.  
All 18 patients suffered with severe pain with a median (IQR) oral morphine equivalent dose 
of 86 (33-195) mg/day. The median (IQR) patient reported pain scores were 9 (9-10) for the 
maximal pain score and 6 (IQR 4-7) for the average pain score.  All 18 patients had pancreatic 
exocrine insufficiency requiring pancreatic enzyme replacement therapy with a median (IQR) 
dose of 290,000 (225,000 - 360,000) lipase units per day. Eleven patients (61%) had overt 
preoperative diabetes mellitus, eight requiring subcutaneous insulin and three required oral 
anti-hyperglycemic medication and seven had pre-diabetes.  Twelve patients had a median 
(IQR) weight loss of 7.5 (5-9.5) kg. was Five patients had radiological biliary obstruction, two 
were clinically jaundiced. 
Pre-Operative Radiological Findings 
All 18 patients had end-stage chronic pancreatitis with vascular involvement (representative 
images from selected patients are presented in Figure 2). Seventeen (94%) patients had varices, 
hepatic portal varices/cavernous transformation in 12 (67%) and gastrosplenic varices in 16 
(89%); 11 patients had both hepatic portal and gastrosplenic varices. Twelve (66%) patients 
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had venous stenosis or occlusion, affecting the splenic vein in all 12 patients and the hepatic 
portal vein/superior mesenteric vein axis in 10 cases. Two (11%) patients had complete portal 
vein occlusion and 5 (28%) patients splenic vein occlusion. Nine (50%) patients had 
splenomegaly and four (22%) patients had ascites. One patient had arterial involvement with 
significant inflammation around the superior mesenteric artery.  
All patients demonstrated pancreatic atrophy estimated radiologically as mild (<50%) in 7 
(39%) patients, moderate (50-75%) in 6 (33%) patients, and severe (>75%) in 5 (28%) patients. 
The median (IQR) radiologically estimated atrophy was 60% (22.5-70%).  
Seventeen (94%) patients had pancreatic parenchymal calcification affecting the head in all 17 
(94%), the neck in 16 (89%), the body in 14 (78%) and the tail in 13 (72%). Ten (56%) patients 
had main pancreatic duct dilatation which affected the pancreatic neck in all 10 patients, the 
body in 8 patients, the head in 4 patients and the tail in 5 patients. Two patients had main 
pancreatic duct strictures, both in the pancreatic neck.  
Eleven (61%) patients had peripancreatic fluid collections, 10 (56%) had pseudocysts and 8 
(44%) had an inflammatory mass of the pancreas. 
 Seven (39%) patients had peripheral organ involvement, 5 (28%) with biliary obstruction, 5 
(28%) with radiologic gastric outlet obstruction, and one patient had an internal pancreato-
peritoneal fistula. 
Patient Fitness, Previous Intervention and Operative Outcomes 
Twelve (67%) patients had a performance status of 0 or 1, three patients were performance 
status 2, two were performance status 3 and one patient had a performance status of 4. The 
ASA grade for 14 patients (77.8%) was 1 or 2 and four patients were ASA grade 3.  
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Four patients had undergone previous pancreatic intervention including a Berne modification 
procedure in two patients, one had an EUS guided pseudocyst-duodenostomy stent insertion, 
and another had minimal access retroperitoneal pancreatic necrosectomy and a Roux-en-Y 
gastrojejunostomy. The nine patients with splenomegaly received pre- and per-operative 
platelet transfusions in order to try to maintain the platelet count. In addition, four patients had 
a splenectomy to control the platelet count: in one patient (the index case) this was a staged 
splenectomy and in three others it was performed synchronously at the beginning of the 
surgery.  
The two initial Livocado procedures were especially complex but established the procedure. In 
first patient (the index case) was a non-drinker with massive splenomegaly, refractory 
thrombocytopenia, cavernous transformation of the hepatic portal vein with multiple varices it 
was impossible continue the surgical procedure because of intra-operative plummeting platelet 
levels. The patient who was the main breadwinner for the family had idiopathic pancreatitis 
and had never ever drunk alcohol. Optimum medical management and high doses of morphine 
could not control the pain resulting in major deleterious impact on social and employment 
circumstances. A second operation with large volume platelet transfusion could only go as far 
as releasing dense adhesions around the pancreas, spleen and diaphragm as the patient had 
undergone a left sided nephrectomy 5 years previously with extensive post-operative 
radiotherapy resulting in malrotation of the transverse colon with dense adhesions in the left 
upper quadrant of the abdominal cavity. An elective splenectomy was only possible on the 
third attempt following splenic vein embolization the day before, but pancreas resection was 
still not possible. The patient developed complications following release of dense adhesions 
related to transverse colon ischemia requiring an extended right hemicolectomy, end ileostomy 
and mucous fistula. The patient went on to undergo a successful Livocado procedure and 
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synchronous ileostomy reversal and  was able to return work. and support the family. This 
index case was the initial inspiration for the Livocado near-total in situ pancreatectomy. 
The second patient presented as an emergency and had required intensive care support with 
complicated chronic pancreatitis secondary to alcohol with portal and splenic vein thrombosis, 
intra-abdominal collections, splenic and peri-splenic abscesses, and sepsis, with a background 
of type 2 diabetes mellitus, COPD, and a previous EUS guided duodeno-pseudocystostomy 
stent insertion. A patient-controlled analgesia system was required delivering on demand 5mg 
morphine bolus with a 5-minute lock-out time. Following one-month intensive care support 
and percutaneous drainage of the abscesses, a decision was made to perform a ‘limited’ 
Livocado procedure was performed due to severe pain and failure to progress. Following pre-
operative splenic artery embolization was performed. Surgery was complex involving a 
complex procedure was performed involving splenectomy, resection of splenic and peri-
splenic abscesses, coring out of 75% of the pancreas from the tail towards the pancreatic head, 
a longitudinal pancreato-jejunostomy and diaphragmatic repair with transversus abdominus 
flap taking 7 hours. Following an initial post-hospitalisation recovery with improvement in 
pain scores and weaning to mild opiates (codeine), pain scores and opiate requirements began 
to increase. At 17 months following the initial procedure the decision was made to complete 
the parenchymal resection in the head completing the A completion formal Livocado procedure 
was undertaken 17 months later following clinical stabilisation. 
All subsequent 16 procedures followed a more straightforward single procedure surgical 
outcome. Overall the median (IQR) operative time was 6 hours 37 minutes (5 hours 17 minutes 
– 7 hours 10 minutes). The median (IQR) hospital length of stay was 13.5 (10 - 21.3) days. All 
patients had chronic pancreatitis on histopathology and 7 (39%) also had focal PanIN 1a or 1b 
lesions. Nine (50%) patients had post-operative complications, two with Clavien-Dindo grade 
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I. 5 with grade II, and one each with grade III and IV. There was no perioperative or 90-day 
mortality. 
Patient Follow-Up 
Median (IQR) length of follow-up was 32.5 (21-45.75) months. Four patients were lost to 
follow-up after a median (IQR) of 25 (19.5-30.5) months, two patients who had moved abroad 
and the other two had stopped attending clinic after 15 months and 29 months. Two patients 
died following hospital readmission, the first from a cardiovascular accident at 3 months, and 
the second from decompensated alcoholic liver disease and emphysematous cystitis with 
Klebsiella pneumoniae secondary sepsis at 19 months.  
Both maximal and average pain scores were significantly improved post-operatively; at 12 
months two-thirds of patients were completely pain free (Figure 3A and B). Opiate analgesia 
use was also significantly reduced post-operatively (Figure 4). 
Postoperatively 17 (94%) patients were diabetic, 14 requiring insulin whilst three managed 
with oral anti-hyperglycemic medications (p=0.041 compared to diabetes pre-operatively). The 
median (IQR) pancreatic exocrine replacement therapy lipase dose increased to 325,000 
(242,500-450,000) lipase units/day post-operatively (p=0.015 compared to pre-operative 
dosage). Pre-operatively only six (33%) patients were employed, but post-operatively 13 (72%) 
patients returned to employment (p=0.01). 
Three patients required re-intervention, one for revision of the jejuno-jejunostomy at 5-months, 
one was treated with IV antibiotics for acute cholangitis at 8 months, and a third required a 
biliary stent for a stricture at the ostium of the bile duct in the cored-out head of the pancreas.  
DISCUSSION 
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This novel operative approach was developed to be able to offer treatment to patients with end-
stage chronic pancreatitis where conventional surgical options were at high risk or technically 
not feasible. Duodenum-preserving pancreatic head resections have been shown to be highly 
effective in improving symptoms.18-22, 33-35 Whilst the duodenum-preserving pancreatic head 
resections such as the Beger, Berne and Frey procedures target disease in the head of the 
pancreas with drainage of functioning tissue in the uncinate and body and tail of the pancreas, 
the Livocado procedure aims to remove all disease parenchyma including the head, uncinate 
process, body, and tail of the pancreas. The contrasting concepts between the Livocado and 
duodenum-preserving pancreatic head resections such as the Frey procedure is shown in 
Figures 5A and 5B. In situations where a classical Kausch-Whipple partial pancreato-
duodenectomy and the duodenum-preserving variants are both possible, the results in pain 
relief are comparable but the Beger-like procedures are superior in terms of post-operative 
complications and can be undertaken in more advanced cases.36  The Hamburg group have 
described the Izbiki procedure with a ‘V’ shaped excision into the main pancreatic duct.37 This 
was initially indicated for small duct disease as a drainage procedure, but was subsequently 
developed and combined with a duodenum-preserving pancreatic head resection.38  Izbicki et 
al described  “ the Hamburg modification, which involved a V-shaped excision of the 
pancreatic body beyond the deep duodenum-preserving head resection, aiming to reach second-
order and third-order pancreatic side branches. The concept behind this V-shaped excision was 
the idea of eliminating potential stenosis and prevention of stenosis that may appear as the 
disease, hypothetically resulting in better long- term outcomes.” 37,38 The indication is for 
patients with dominant head disease. In contrast the Livocado procedure is for patients with 
involvement of the whole gland requiring a total pancreatotomy with removal of all diseased 




The management of CP has followed a step-up approach, starting with lifestyle modification, 
medical therapy including analgesia, followed by interventional endoscopy, and finally 
surgical resection is offered when all other measures have failed.2, 3, 18, 25 There is now emerging 
data in support of improved outcomes in early (<3 years after symptom onset) versus later 
surgery in more advanced disease stages in terms of long term pain relief, reduced risk of 
pancreatic insufficiency and reduced rates of reintervention.25, 39 However, the final options 
available are dependent on the extent of the disease, pancreatic exocrine function, presence of 
diabetes mellitus, and involvement of adjacent structures.  
Vascular involvement is associated with major surgical risk, with splenic or portal vein 
thrombosis seen in 2.5-25% of all cases and in 10-37% of patients with alcohol-related CP, and 
is a relative contraindication to surgery.11-13 The Livocado procedure was developed with the 
intention of removing as much diseased pancreas as possible without the necessity to enter into 
vascular planes or undertake vascular resections. The Hamburg modification of the duodenum-
preserving pancreatic head resection resembles more the Beger procedure when combined with 
a Puestow lateral pancreato-jejunostomy described originally in 1989.38, 40 The Hamburg 
modification aims to a perform “a longitudinal V-shaped excision of the ventral aspect of the 
body and the tail of the pancreas” in order to provide “sufficient drainage of the second-order 
and third-order pancreatic side branches”.40 The Livocado procedure aims at a formal near-
total pancreatectomy leaving only a rim of fibrous tissue for the pancreato-jejunostomy. The 
difference is reflected in the degree of postoperative diabetes mellitus of 94% in this study and 
69% with the Hamburg modification.38 In this Livocado series all patients had vascular 
involvement, compared to 32 (6.45%) out 496 patients undergoing the Hamburg procedure 
reported in 2011.12  Series on surgery of patients with chronic pancreatitis and vascular 
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involvement have reported increased operative time, operative bleeding, post-operative 
morbidity and mortality.11, 12, 41, 42 In this Livocado series there was morbidity Clavien-Dindo 
grade  III of 11% and no deaths compared to previous reports of 43.8-70.6% and 3-63% 
respectively.11, 12, 41, 42 
The Livocado procedure resulted in significant improvements in pain score and daily opiate 
requirements. Both were significantly improved by first follow-up at 1 month and continued to 
improve at 6 months before reaching the best point at 12-months, when two-thirds of patients 
were pain free. Patients undergoing the Livocado procedure compared with the previously 
described Liverpool Duodenum Preserving and Spleen Preserving Near-Total Pancreatectomy 
(DPSPTP), were respectively older (48.5 versus 40.8 years), had higher previous alcohol 
consumption (200 versus 140 units/day), smoked more (26 versus 20 pack-years), reported 
higher maximal pain scores (9 versus 8), and required higher daily opiate doses (86 versus 50 
mg/day).24 Patients in the Livocado group had greater vascular involvement (100% versus 
27%) and peripancreatic organ involvement but with similar ASA grades.24 Despite having 
higher pre-operative pain scores, higher opiate requirements and more peripheral organ and 
vascular involvement, patients undergoing the Livocado procedure did equally as well as those 
who underwent DPSPTP in the later era (post-2003) in terms of length of stay (13.5 versus 
13.5 days respectively), peri-operative complications (Clavien-Dindo  III) (11.1% versus 
12.5%), and late complications (27.8% versus 33%), and also no 90-day mortality with either 
procedure.24 Post-operative pain scores and opiate dose reductions were similarly significantly 
improved following both operations and most patients returned to work (72% versus 58%).24 
These data compare well with that from published series of total pancreatectomy with reported 
mortality ranging from 2.9 to 20.6% and complication rates of 15.3 to 51.9.36 Although there 
is interest in total pancreatectomy with islet auto-transplantation in the treatment of chronic 
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pancreatitis, this procedure is not suitable for adults with CP who have end stage disease with 
exocrine and complete endocrine failure with few or no functioning islets present.43 
In conclusion, the in situ near-total pancreatectomy Livocado procedure enabled effective 
surgical treatment to a selective group of patients with complex end stage chronic pancreatitis 
with debilitating pain who would otherwise be at high risk from conventional total 
pancreatectomy. 
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FIGURE LEGENDS 
Figure 1. Operative photographs demonstrating the key stages of the Livocado procedure: (A) 
The ventral pancreas is exposed and haemostatic sutures are placed around the entire pancreatic 
margin.  (B) A duodenum preserving pancreatic head resection with near-total coring extended 
across the pancreatic neck and along the length of the body and tail is performed.  (C) 
Longitudinal pancreato-jejunostomy using a Roux-en-Y reconstructive limb. 
Figure 2. Preoperative CT images from four different patients: (A) Parenchymal atrophy and 
main pancreatic duct dilatation with diffuse parenchymal and ductal calculi. Stenosis of the 
splenic vein and varices. (B) Hepatic portal and splenic vein thrombosis, and splenomegaly, 
with splenic and gastric vein varices. Extra-hepatic bile duct occlusion with intra-hepatic duct 
dilatation and a previous left nephrectomy. (C) Pancreatic parenchymal atrophy with diffuse 
pancreatic parenchymal and ductal calculi and upstream main pancreatic duct dilatation. 
Splenic and gastric vein varices. (D) Duodeno-pseudocystic covered stent, non-occlusive 
hepatic vein thrombus and splenic vein occlusion, upper abdominal varices, splenomegaly with 
inferior pole infarction and large subcapsular collection. Left sided pleural effusion. 
Figure 3. Pain scores preoperatively and during follow-up. (A) Maximal reported pain 
scores; and (B) Average reported pain score. 
Figure 4. Equianalgesic oral morphine equivalent dose pre-operatively and during follow-up. 
Median, IQR and range.  
Figure 5.  Whereas the duodenum-preserving pancreatic head resections such as the Frey 
procedure (5A) aim to remove part of the head of the gland and improve drainage of the central 
and side branch pancreatic ducts, the Livocado procedure aims to remove all of the diseased 
parenchyma except for a rim of tissue posteriorly to avoid dissection into vascular planes and 
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allow enough fibrous tissue around the rim for a secure Roux-en-Y pancreato-jejunostomy 
(5B). 
LAOS  4. January 2021 
LIVOCADO procedure for end-staged CP 
Title: The in situ near-total pancreatectomy (LIVOCADO) procedure for end staged chronic 
pancreatitis. 
Authors: Ryan D. Baron (PhD) 1, ORCID ID: 0000-0002-3194-6689 
Andrea R.G. Sheel (MRCS) 1,2, ORCID ID: 0000-0002-4980-956X 
Ammad Farooq (MD)3,  
Jörg Kleeff (MD)4, ORCID ID: 0000-0003-3432-6669 
Pietro Contin (MD)5,  
Christopher M. Halloran (MD) 1,2, ORCID ID: 0000-0002-5471-4178 
John P. Neoptolemos (MD) 5, ORCID ID: 0000-0002-6201-7399 
 
Affiliations:  
1Department of Pancreato-Biliary Surgery, The Royal Liverpool University Hospital, 
Liverpool, UK.  
2 Department of Clinical Cancer Medicine, Institute of Translational Medicine, The University 
of Liverpool, Liverpool, UK.  
3Department of Radiology, The Royal Liverpool University Hospital, Liverpool, UK.  
4Department of Visceral, Vascular and Endocrine Surgery, Martin, Halle (Saale), Germany.  
5 Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Im 
Neuenheimer Feld 420, 69120 Heidelberg, Baden-Württemberg, Germany. 
 
Corresponding author / Requests for reprints: 
Prof. Dr. med. John Neoptolemos, MA, MB, BChir, MD, FRCS, FMedSci, MAE 
Professor of Surgery 
Department of General, Visceral and Transplantation Surgery 
University of Heidelberg 
Revised manuscript clean version Click here to view linked References
 1 
Im Neuenheimer Feld 420 
69120 Heidelberg 
Baden-Württemberg, Germany 
Tel: 0049 6221 56 32880   
Fax: 0049 6221 56 5538   
john.neoptolemos@med.uni-heidelberg.de 
 
Running head: In-situ near-total pancreatectomy for end-staged chronic pancreatitis. 
 
Key words: Surgery; extrahepatic portal hypertension; pain; varices; Beger operation; Frey 
operation. 
 
Abstract word count = 250 






Purpose: Total pancreatectomy for severe pain in end stage chronic pancreatitis may be the 
only option but with vascular involvement this is usually too high risk and/or technically not 
feasible. The purpose of the study was to present the clinical outcomes of a novel procedure in 
severe chronic pancreatitis complicated by uncontrollable pain and vascular involvement. 
Methods: We describe an in-situ near-total pancreatectomy that avoids peri-pancreatic 
vascular dissection (Livocado procedure) and report on surgical and clinical outcomes. 
Results: The Livocado procedure was carried out on 18 (3.9%) of 465 patients undergoing 
surgery for chronic pancreatitis. There were 13 men and 5 women with a median (IQR) age of 
48.5 (42.4-57) years and weight of 60.7 (58.0-75.0) Kg. All had severe pain and vascular 
involvement; 17 had pancreatic parenchymal calcification; the median (IQR) oral morphine 
equivalent dose requirement was 86 (33-195) mg/day. The median (IQR) maximal pain scores 
were 9 (9-10); the average pain score was 6 (IQR 4-7).  There was no perioperative or 90-day 
mortality. At a median (IQR) follow-up of 32.5 (21-45.75) months both maximal and average 
pain scores were significantly improved post-operatively, and at 12 months two-thirds of 
patients were completely pain free. Six (33%) patients had employment pre-operatively versus 
13 (72%) post-operatively (p=0.01). 
Conclusions: The Livocado procedure was safe and carried out successfully in patients with 
chronic pancreatitis with vascular involvement where other procedures would be 
contraindicated. Perioperative outcomes, post-operative pain scores and employment 






Chronic pancreatitis is a complex inflammatory syndrome of the pancreas with pain as the 
predominant symptom.1 It affects individuals with genetic, environmental and/or other risk 
factors who develop persistent pathological responses to parenchymal injury or stress.2, 3 CP is 
a major source of morbidity with the incidence and prevalence estimated to be around 5-12 per 
105 per year and 50 per 105 respectively.4-7 4-7 Chronic pancreatitis carries a heavy disease 
burden including chronic pain, pancreatic endocrine and exocrine failure leading to diabetes 
mellitus and malnutrition, lower quality of life, serious long-term complications including a 5–
25-fold risk of pancreatic cancer, and social stigma, with a reduced life expectancy.8-10 
The long-term morphological sequelae of chronic inflammation, fibrosis and loss of 
parenchymal architecture result in ductal and parenchymal calcifications, ductal strictures, 
inflammatory masses, pseudocysts, biliary and duodenal obstruction, pancreatic fistulae, and 
pancreatic ascites.2, 3, 8, 9 Vascular complications include porto-mesenteric venous compression 
or occlusion, extra-hepatic portal hypertension, splenic-portal-thrombosis, venous 
collateralization and pseudo-aneurysm.2, 11-14 Longitudinal studies show that 40-75% of CP 
patients require surgical intervention most commonly for intractable pain.15-18 Duodenum- 
preserving pancreatic head resection (DPPHR) notably the Beger, Frey and Berne procedures 
are effective for head dominant disease, providing decompression of the duodenum, hepatic 
portal vein, main pancreatic duct and intra-pancreatic bile duct.19-22  
There remains a role for total pancreatectomy in a highly select group of patients with end 
staged CP affecting the entire pancreas,  intractable pain and pre-existing endocrine failure.2, 
23-25  Total pancreatectomy in chronic pancreatitis is however associated with substantial 
morbidity and mortality especially in cases with vascular involvement. The aim of this study 
was to evaluate the early and late outcomes of a novel surgical procedure which offers an 
alternative for patients who would otherwise require a total pancreatectomy. This procedure 
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combines a duodenum preserving pancreatic head resection with extended coring of the neck, 
body and tail of the pancreas, leaving only an outer rim of fibrosed tissue, which is anastomosed 
to a Roux-en-Y jejunal limb.  
METHODS 
Study Design 
This is a single-center cohort series of consecutive patients with chronic pancreatitis referred 
to the Liverpool Pancreas Centre for further evaluation between January 1997 and May 2020. 
The in-situ near-total pancreatectomy procedure was first introduced on 30 December 2014 
and the last procedure was undertaken on 11 February 2020. The data lock for all patients was 
18 May 2020. A prospectively maintained database recorded demographic, clinical, 
radiological, genetic and histopathological data along with the patient’s performance status and 
employment status during initial patient clinical assessment in the pancreas outpatient clinic. 
All patients were asked to complete patient reported pain scores on a visual analogue scale 
scores recorded on a 10-point Likert scale (0–10), including maximal (“worst”) pain and 
average pain. Patients were followed up after discharge in accordance with local clinical 
protocol, which comprised of routine assessment at 4-6 weeks, 3, 6 and 12 months, then 
annually with additional review as clinically required. Data collected at follow-up included 
weight, diabetes status, presence of steatorrhea, pancreatic enzyme replacement dosage, 
analgesia requirements, employment status and pain scores. The equianalgesic equivalence to 
oral morphine was calculated for all opiate medications as recommended by the Royal College 
of Anaesthetists of England.26 Complications were graded according to Dindo et al.27 Data 
were censored at the point when patients were discharged, lost to follow-up or died.  
Diagnosis of Chronic Pancreatitis 
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The diagnosis of CP was based on clinical and radiological criteria and confirmed in all patients 
following histopathological assessment of operative specimens.28, 29 CP secondary to alcohol 
required alcohol consumption of ≥ 62 units per week for ≥ 1 year.30 Patients with idiopathic 
CP were classified into two groups: (1) idiopathic with no genetic background and with a 
genetic background.31 The presence of pancreatic exocrine insufficiency was based on clinical 
assessment, and the response of steatorrhea to pancreatic enzyme replacement therapy. 
Radiological Review 
Vascular assessment was made on the basis of a preoperative pancreas protocol CT including 
arterial and portal venous phase imaging. All CT scans were reviewed and scored 
retrospectively by a specialist pancreatic radiologist blinded to patient outcomes.28  
Eligibility Criteria 
The in-situ near-total pancreatectomy procedure was only considered in a highly selected small 
subset of patients that had severe end stage chronic pancreatitis where the whole pancreas was 
diseased with exocrine and endocrine insufficiency and daily debilitating abdominal pain 
unresponsive to medical treatment, and abstinence from alcohol for more than 6 months. 
Operative Description 
The duodenum and pancreas were exposed as described previously and the duodenum was 
fully Kocherized.23 The pancreatic margins were defined by dividing the superior and inferior 
peritoneal reflections and the right gastroepiploic vein (or the gastrocolic trunk of Henle when 
required) was ligated and divided to fully reflect the antrum of the stomach off the anterior 
head of the pancreas. Hemostatic sutures are placed around the entire pancreatic margin (Figure 
1A). The pancreatic head was cored out following the principles of the Berne modification of 
the Beger procedure.32 This resection was continued across the neck of the pancreas taking 
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extreme care of the superior mesenteric, hepatic portal venous axis and along the entire length 
of the body and tail of the pancreas. All pancreatic tissue anterior to the main pancreatic duct 
and as much of the tissue superior, inferior and posterior to the duct as possible was cored out 
leaving only a thin fibrotic outer rim of pancreas. Because of the dense fibrous tissue and 
calcification, a combination sharp dissection with a scalpel and scissors was required. This is 
analogous to a cored-out avocado providing the term Livocado in part reference to its origin in 
Liverpool. A cholecystectomy was then performed, and the cystic duct was catheterized using 
an umbilical feeding catheter. This tube was palpated within the cored out pancreatic head and 
the intrapancreatic bile duct was incised and widely marsupialized using 4 to 6 interrupted 4-0   
sutures (Figure 1B). The jejunum was divided using a linear cutter-stapler and the distal limb 
was delivered through an incised transverse mesocolon defect as a Roux-en-Y. The jejunal 
limb was opened by a diathermy longitudinal incision along the anti-mesenteric border and 
sutured to the pancreatic rim using continuous 4-0 PDS sutures between stays as follows. The 
distal end of the limb was first parachuted to the tip of the tail of the pancreas using interrupted 
stay sutures. The inferior pancreatic rim was then sutured to the jejunal enterotomy using a 
continuous suture and full thickness bites, across the neck and around the inferior aspect of the 
cored-out head and uncinated process. The superior border of the pancreatic rim was then 
continuously sutured to the jejunal enterotomy again from tail to head. Along the 
pancreatoduodenal groove the jejunal enterotomy could be sutured to the medial duodenal wall 
if needed. The superior and inferior sutures were then tied together when meeting (Figure 1C). 
The gastroduodenal limb was then anastomosed side-to-side to the pancreatic limb to complete 
the Roux-en-Y. 
Eligibility Criteria 
The in-situ near-total pancreatectomy procedure was only considered in a highly selected small 
subset of patients that had all of the following criteria. 
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(1) severe end stage chronic pancreatitis where the whole pancreas was diseased with 
exocrine/endocrine failure; 
(2) daily debilitating abdominal pain unresponsive to medical treatment; 
(3) duodenum-and spleen-preserving near-total pancreatectomy or standard total 
pancreatectomy was technically not feasible, notably due to vascular and/or other intra-
abdominal complications; 
(4) demonstrable abstinence from alcohol for more than 6 months.  
Statistical Analysis 
Continuous variables are presented as median and interquartile range (IQR). Statistical 
comparison was by using the Wilcoxon Rank test for paired data based on a 2-tailed alpha. 
Categorical variables are presented as frequency and percentage and were analyzed using the 
Χ2 test, or Fishers exact probability test. Significance was set at the 5% level (p < 0.05). SPSS 
v24 was used for the analyses. 
RESULTS 
Patient Demographics and Chronic Pancreatitis Characteristics 
Between January 1997 and May 2020 approximately 1200 patients with a diagnosis of chronic 
pancreatitis were referred to the Liverpool Pancreas Centre for further evaluation. Surgery was 
undertaken in 465 patients comprising a pylorus preserving partial pancreato-duodenectomy in 
133 (28.6%), a Beger’s duodenum head resection in 130 (28.0%), a classical Kausch-Whipple 
pancreata-duodenectomy in 8 (1.7%) patients, a left pancreatectomy (with or without spleen 
preservation) in 43 (9.3%), various drainage procedures in 67 (14.4%) patients (including 
Partington-Rochelle, Izbicki V-procedure, and pseudocyst-jejunostomy), and total 
pancreatectomy in 66 (14.2%) patients (including duodenum and spleen preserving near-total 
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pancreatectomy in 51). The remaining 18 (3.9%) patients (13 men and 5 women) underwent a 
Livocado resection all with severe uncontrollable pain as the primary indication, with baseline 
demographic and operative details shown in Table 1. The median (IQR) age was 48.5 (42.4-
57) years and median (IQR) weight 60.7 (58.0-75.0) Kg and a BMI 21.2 (20.1-25.5). The 
median (IQR) duration of symptoms at the time of surgery was 4 (2–10.3) years. The etiology 
was excess alcohol in 12 with a prior median (IQR) consumption of 200 (100 – 245) units per 
week. Six patients were idiopathic of whom one had a genetic background (a heterozygous 
SPINK-1 pAsn34Ser variant and a heterozygous CFTR pArg117His mutation). 17 patients had 
a history of tobacco smoking, of whom 13 were current smokers, with a median (IQR) 26.3 
(19.2-37) pack years; one patient had never smoked.  
All 18 patients suffered with severe pain with a median (IQR) oral morphine equivalent dose 
of 86 (33-195) mg/day. The median (IQR) patient reported pain scores were 9 (9-10) for the 
maximal pain score and 6 (IQR 4-7) for the average pain score.  All 18 patients had pancreatic 
exocrine insufficiency requiring pancreatic enzyme replacement therapy with a median (IQR) 
dose of 290,000 (225,000 - 360,000) lipase units per day. Eleven patients (61%) had overt 
preoperative diabetes mellitus, eight requiring subcutaneous insulin and three required oral 
anti-hyperglycemic medication and seven had pre-diabetes.  Twelve patients had a median 
(IQR) weight loss of 7.5 (5-9.5) kg. was Five patients had radiological biliary obstruction, two 
were clinically jaundiced. 
Pre-Operative Radiological Findings 
All 18 patients had end-stage chronic pancreatitis with vascular involvement (representative 
images from selected patients are presented in Figure 2). Seventeen (94%) patients had varices, 
hepatic portal varices/cavernous transformation in 12 (67%) and gastrosplenic varices in 16 
(89%); 11 patients had both hepatic portal and gastrosplenic varices. Twelve (66%) patients 
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had venous stenosis or occlusion, affecting the splenic vein in all 12 patients and the hepatic 
portal vein/superior mesenteric vein axis in 10 cases. Two (11%) patients had complete portal 
vein occlusion and 5 (28%) patients splenic vein occlusion. Nine (50%) patients had 
splenomegaly and four (22%) patients had ascites. One patient had arterial involvement with 
significant inflammation around the superior mesenteric artery.  
All patients demonstrated pancreatic atrophy estimated radiologically as mild (<50%) in 7 
(39%) patients, moderate (50-75%) in 6 (33%) patients, and severe (>75%) in 5 (28%) patients. 
The median (IQR) radiologically estimated atrophy was 60% (22.5-70%).  
Seventeen (94%) patients had pancreatic parenchymal calcification affecting the head in all 17 
(94%), the neck in 16 (89%), the body in 14 (78%) and the tail in 13 (72%). Ten (56%) patients 
had main pancreatic duct dilatation which affected the pancreatic neck in all 10 patients, the 
body in 8 patients, the head in 4 patients and the tail in 5 patients. Two patients had main 
pancreatic duct strictures, both in the pancreatic neck.  
Eleven (61%) patients had peripancreatic fluid collections, 10 (56%) had pseudocysts and 8 
(44%) had an inflammatory mass of the pancreas. 
 Seven (39%) patients had peripheral organ involvement, 5 (28%) with biliary obstruction, 5 
(28%) with radiologic gastric outlet obstruction, and one patient had an internal pancreato-
peritoneal fistula. 
Patient Fitness, Previous Intervention and Operative Outcomes 
Twelve (67%) patients had a performance status of 0 or 1, three patients were performance 
status 2, two were performance status 3 and one patient had a performance status of 4. The 
ASA grade for 14 patients (77.8%) was 1 or 2 and four patients were ASA grade 3.  
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Four patients had undergone previous pancreatic intervention including a Berne modification 
procedure in two patients, one had an EUS guided pseudocyst-duodenostomy stent insertion, 
and another had minimal access retroperitoneal pancreatic necrosectomy and a Roux-en-Y 
gastrojejunostomy. The nine patients with splenomegaly received pre- and per-operative 
platelet transfusions in order to try to maintain the platelet count. In addition, four patients had 
a splenectomy to control the platelet count: in one patient (the index case) this was a staged 
splenectomy and in three others it was performed synchronously at the beginning of the 
surgery.  
The two initial Livocado procedures were especially complex but established the procedure. In 
first patient (the index case) was a non-drinker with massive splenomegaly, refractory 
thrombocytopenia, cavernous transformation of the hepatic portal vein with multiple varices it 
was impossible continue the surgical procedure because of intra-operative plummeting platelet 
levels. A second operation with large volume platelet transfusion could only go as far as 
releasing dense adhesions around the pancreas, spleen and diaphragm as the patient had 
undergone a left sided nephrectomy 5 years previously with extensive post-operative 
radiotherapy resulting in malrotation of the transverse colon with dense adhesions in the left 
upper quadrant of the abdominal cavity. An elective splenectomy was only possible on the 
third attempt following splenic vein embolization the day before, but pancreas resection was 
still not possible. The patient developed complications following release of dense adhesions 
related to transverse colon ischemia requiring an extended right hemicolectomy, end ileostomy 
and mucous fistula. The patient went on to undergo a successful Livocado procedure and 
synchronous ileostomy reversal and was able to return work.  
The second patient presented as an emergency and had required intensive care support with 
complicated chronic pancreatitis secondary to alcohol with portal and splenic vein thrombosis, 
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intra-abdominal collections, splenic and peri-splenic abscesses, and sepsis, with a background 
of type 2 diabetes mellitus, COPD, and a previous EUS guided duodeno-pseudocystostomy 
stent insertion. Following one-month intensive care support and percutaneous drainage of the 
abscesses, a ‘limited’ Livocado procedure was performed. Following pre-operative splenic 
artery embolization, a complex procedure was performed involving splenectomy, resection of 
splenic and peri-splenic abscesses, coring out of 75% of the pancreas from the tail towards the 
pancreatic head, a longitudinal pancreato-jejunostomy and diaphragmatic repair with 
transversus abdominus flap A completion formal Livocado procedure was undertaken 17 
months later following clinical stabilisation. 
All subsequent 16 procedures followed a more straightforward single procedure surgical 
outcome. Overall the median (IQR) operative time was 6 hours 37 minutes (5 hours 17 minutes 
– 7 hours 10 minutes). The median (IQR) hospital length of stay was 13.5 (10 - 21.3) days. All 
patients had chronic pancreatitis on histopathology and 7 (39%) also had focal PanIN 1a or 1b 
lesions. Nine (50%) patients had post-operative complications, two with Clavien-Dindo grade 
I. 5 with grade II, and one each with grade III and IV. There was no perioperative or 90-day 
mortality. 
Patient Follow-Up 
Median (IQR) length of follow-up was 32.5 (21-45.75) months. Four patients were lost to 
follow-up after a median (IQR) of 25 (19.5-30.5) months, two patients who had moved abroad 
and the other two had stopped attending clinic after 15 months and 29 months. Two patients 
died following hospital readmission, the first from a cardiovascular accident at 3 months, and 
the second from decompensated alcoholic liver disease and emphysematous cystitis with 
Klebsiella pneumoniae secondary sepsis at 19 months.  
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Both maximal and average pain scores were significantly improved post-operatively; at 12 
months two-thirds of patients were completely pain free (Figure 3A and B). Opiate analgesia 
use was also significantly reduced post-operatively (Figure 4). 
Postoperatively 17 (94%) patients were diabetic, 14 requiring insulin whilst three managed 
with oral anti-hyperglycemic medications (p=0.041 compared to diabetes pre-operatively). The 
median (IQR) pancreatic exocrine replacement therapy lipase dose increased to 325,000 
(242,500-450,000) lipase units/day post-operatively (p=0.015 compared to pre-operative 
dosage). Pre-operatively only six (33%) patients were employed, but post-operatively 13 (72%) 
patients returned to employment (p=0.01). 
Three patients required re-intervention, one for revision of the jejuno-jejunostomy at 5-months, 
one was treated with IV antibiotics for acute cholangitis at 8 months, and a third required a 
biliary stent for a stricture at the ostium of the bile duct in the cored-out head of the pancreas.  
DISCUSSION 
This novel operative approach was developed to be able to offer treatment to patients with end-
stage chronic pancreatitis where conventional surgical options were at high risk or technically 
not feasible. Duodenum-preserving pancreatic head resections have been shown to be highly 
effective in improving symptoms.18-22, 33-35 Whilst the duodenum-preserving pancreatic head 
resections such as the Beger, Berne and Frey procedures target disease in the head of the 
pancreas with drainage of functioning tissue in the uncinate and body and tail of the pancreas, 
the Livocado procedure aims to remove all disease parenchyma including the head, uncinate 
process, body, and tail of the pancreas. The contrasting concepts between the Livocado and 
duodenum-preserving pancreatic head resections such as the Frey procedure is shown in 
Figures 5A and 5B. In situations where a classical Kausch-Whipple partial pancreato-
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duodenectomy and the duodenum-preserving variants are both possible, the results in pain 
relief are comparable but the Beger-like procedures are superior in terms of post-operative 
complications and can be undertaken in more advanced cases.36  The Hamburg group have 
described the Izbiki procedure with a ‘V’ shaped excision into the main pancreatic duct.37 This 
was initially indicated for small duct disease as a drainage procedure, but was subsequently 
developed and combined with a duodenum-preserving pancreatic head resection.38  As Izbicki 
et al described  “ the Hamburg modification, which involved a V-shaped excision of the 
pancreatic body beyond the deep duodenum-preserving head resection, aiming to reach second-
order and third-order pancreatic side branches. The concept behind this V-shaped excision was 
the idea of eliminating potential stenosis and prevention of stenosis that may appear as the 
disease, hypothetically resulting in better long- term outcomes.” 37,38 The indication is for 
patients with dominant head disease. In contrast the Livocado procedure is for patients with 
involvement of the whole gland requiring a total pancreatotomy with removal of all diseased 
tissue but leaving a posterior capsule in patients at high risk because of vascular involvement. 
 
 
The management of CP has followed a step-up approach, starting with lifestyle modification, 
medical therapy including analgesia, followed by interventional endoscopy, and finally 
surgical resection is offered when all other measures have failed.2, 3, 18, 25 There is now emerging 
data in support of improved outcomes in early (<3 years after symptom onset) versus later 
surgery in more advanced disease stages in terms of long term pain relief, reduced risk of 
pancreatic insufficiency and reduced rates of reintervention.25, 39 However, the final options 
available are dependent on the extent of the disease, pancreatic exocrine function, presence of 
diabetes mellitus, and involvement of adjacent structures.  
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Vascular involvement is associated with major surgical risk, with splenic or portal vein 
thrombosis seen in 2.5-25% of all cases and in 10-37% of patients with alcohol-related CP, and 
is a relative contraindication to surgery.11-13 The Livocado procedure was developed with the 
intention of removing as much diseased pancreas as possible without the necessity to enter into 
vascular planes or undertake vascular resections. The Hamburg modification of the duodenum-
preserving pancreatic head resection resembles more the Beger procedure when combined with 
a Puestow lateral pancreato-jejunostomy described originally in 1989.38, 40 The Hamburg 
modification aims to a perform “a longitudinal V-shaped excision of the ventral aspect of the 
body and the tail of the pancreas” in order to provide “sufficient drainage of the second-order 
and third-order pancreatic side branches”.40 The Livocado procedure aims at a formal near-
total pancreatectomy leaving only a rim of fibrous tissue for the pancreato-jejunostomy. The 
difference is reflected in the degree of postoperative diabetes mellitus of 94% in this study and 
69% with the Hamburg modification.38 In this Livocado series all patients had vascular 
involvement, compared to 32 (6.45%) out 496 patients undergoing the Hamburg procedure 
reported in 2011.12  Series on surgery of patients with chronic pancreatitis and vascular 
involvement have reported increased operative time, operative bleeding, post-operative 
morbidity and mortality.11, 12, 41, 42 In this Livocado series there was morbidity Clavien-Dindo 
grade  III of 11% and no deaths compared to previous reports of 43.8-70.6% and 3-63% 
respectively.11, 12, 41, 42 
The Livocado procedure resulted in significant improvements in pain score and daily opiate 
requirements. Both were significantly improved by first follow-up at 1 month and continued to 
improve at 6 months before reaching the best point at 12-months, when two-thirds of patients 
were pain free. Patients undergoing the Livocado procedure compared with the previously 
described Liverpool Duodenum Preserving and Spleen Preserving Near-Total Pancreatectomy 
(DPSPTP), were respectively older (48.5 versus 40.8 years), had higher previous alcohol 
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consumption (200 versus 140 units/day), smoked more (26 versus 20 pack-years), reported 
higher maximal pain scores (9 versus 8), and required higher daily opiate doses (86 versus 50 
mg/day).24 Patients in the Livocado group had greater vascular involvement (100% versus 
27%) and peripancreatic organ involvement but with similar ASA grades.24 Despite having 
higher pre-operative pain scores, higher opiate requirements and more peripheral organ and 
vascular involvement, patients undergoing the Livocado procedure did equally as well as those 
who underwent DPSPTP in the later era (post-2003) in terms of length of stay (13.5 versus 
13.5 days respectively), peri-operative complications (Clavien-Dindo  III) (11.1% versus 
12.5%), and late complications (27.8% versus 33%), and also no 90-day mortality with either 
procedure.24 Post-operative pain scores and opiate dose reductions were similarly significantly 
improved following both operations and most patients returned to work (72% versus 58%).24 
These data compare well with that from published series of total pancreatectomy with reported 
mortality ranging from 2.9 to 20.6% and complication rates of 15.3 to 51.9.36 Although there 
is interest in total pancreatectomy with islet auto-transplantation in the treatment of chronic 
pancreatitis, this procedure is not suitable for adults with CP who have end stage disease with 
exocrine and complete endocrine failure with few or no functioning islets present.43 
In conclusion, the in situ near-total pancreatectomy Livocado procedure enabled effective 
surgical treatment to a selective group of patients with complex end stage chronic pancreatitis 
with debilitating pain who would otherwise be at high risk from conventional total 
pancreatectomy. 
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FIGURE LEGENDS 
Figure 1. Operative photographs demonstrating the key stages of the Livocado procedure: (A) 
The ventral pancreas is exposed and haemostatic sutures are placed around the entire pancreatic 
margin.  (B) A duodenum preserving pancreatic head resection with near-total coring extended 
across the pancreatic neck and along the length of the body and tail is performed.  (C) 
Longitudinal pancreato-jejunostomy using a Roux-en-Y reconstructive limb. 
Figure 2. Preoperative CT images from four different patients: (A) Parenchymal atrophy and 
main pancreatic duct dilatation with diffuse parenchymal and ductal calculi. Stenosis of the 
splenic vein and varices. (B) Hepatic portal and splenic vein thrombosis, and splenomegaly, 
with splenic and gastric vein varices. Extra-hepatic bile duct occlusion with intra-hepatic duct 
dilatation and a previous left nephrectomy. (C) Pancreatic parenchymal atrophy with diffuse 
pancreatic parenchymal and ductal calculi and upstream main pancreatic duct dilatation. 
Splenic and gastric vein varices. (D) Duodeno-pseudocystic covered stent, non-occlusive 
hepatic vein thrombus and splenic vein occlusion, upper abdominal varices, splenomegaly with 
inferior pole infarction and large subcapsular collection. Left sided pleural effusion. 
Figure 3. Pain scores preoperatively and during follow-up. (A) Maximal reported pain 
scores; and (B) Average reported pain score. 
Figure 4. Equianalgesic oral morphine equivalent dose pre-operatively and during follow-up. 
Median, IQR and range.  
Figure 5.  Whereas the duodenum-preserving pancreatic head resections such as the Frey 
procedure (5A) aim to remove part of the head of the gland and improve drainage of the central 
and side branch pancreatic ducts, the Livocado procedure aims to remove all of the diseased 
parenchyma except for a rim of tissue posteriorly to avoid dissection into vascular planes and 
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allow enough fibrous tissue around the rim for a secure Roux-en-Y pancreato-jejunostomy 
(5B). 
Figure 1A Click here to access/download;Figure;LIVOCADO LAOS 1A.tiff
Figure 1B Click here to access/download;Figure;LIVOCADO 1B.jpeg
Figure 1C Click here to access/download;Figure;LIVOCADO 1C.jpg
Figure 2 Click here to access/download;Figure;LIVOCADO LAOS Figure 2.tiff
Figure 3 Click here to access/download;Figure;LIVOCADO LAOS  Figure 3.tiff
Figure 4 Click here to access/download;Figure;LIVOCADO LAOS Figure 4.tiff
Figure 5A Click here to access/download;Figure;Frey LAOS Fig 5A.jpg
Figure 5B Click here to access/download;Figure;Livocado Fig 5B.jpg
TABLE 1.  Details of patient baseline demographic, operative details, and outcomes. 
Clinical variables Frequency  
Total patients 18 
Men 13 (72%) 
Age, years:  median (IQR) 48.5 (42.5-57.0) 
Weight, Kg:  median (IQR) 60.7 (58.0-75.0) 
Body mass index:  median (IQR) 23.8 (21.3-27.8) 
Symptoms  
Primary symptom severe pain 18 (100%) 
Pancreatic exocrine insufficiency 18 (100%) 
1PERT, lipase units:  median (IQR) 290,000 (225,000- 350,000) 
Diabetes mellitus 11 (61%) 
Risk factors  
Alcohol (>62 units per week for > 1year):  median (IQR) 12 (67%) 
Alcohol, units/week:  median (IQR) 200 (100-245) 
Idiopathic/risk mutation 6 (33%) 
Current Smokers 13 (72%) 
Ever Smokers 17 (94%) 
Pack years:  median (IQR) 26.3 (19.2-37.0) 
Previous Surgery  
Beger’s Procedure 2 (11%) 
Splenectomy 1 (6%) 
Minimal access retroperitoneal necrosectomy 1 (6%) 
EUS guided pseudocyst-duodenostomy 1 (6%) 
Analgesia: Equianalgesic morphine dose, mg/day:  median 
(IQR) 
86 (33-195) 
Preoperative Pain Score  
Maximal Pain:  median (IQR) 9 (9-10) 
Average Pain:  median (IQR) 6 (4-7) 
Performance status  
0 7 (39%) 
1 5 (28%) 
2 4 (17%) 
3 2 (11%) 
4 1 (6%) 
ASA Grade  
I 1 (6%) 
II 13 (72%) 
III 4 (22%) 
Pre-op employment status: Employed 6 (33%) 
Radiological Imaging  
Vascular involvement 18 (100%) 
Porto-mesenteric vein occlusion 2 (11%) 
Porto-mesenteric vein compression 10 (56%) 
Splenic vein occlusion 5 (28%) 
Splenic vein compression 12 (67%) 
Extrahepatic portal hypertension 13 (72%) 
Portal and/or gastrosplenic varices 17 (94%) 
Portal varices and/or cavernous transformation 12 (67%) 
Gastrosplenic varices 16 (89%) 
Splenomegaly 9 (50%) 
Arterial involvement 1 (6%) 
Ascites 4 (22%) 
Pancreatic atrophy 18 (100%) 
- Mild (<50%) atrophy 7 (39%) 
- Moderate (50-75%) atrophy 6 (33%) 
- Severe (>80%) atrophy 5 (28%) 
Table 1
1PERT=pancreas enzyme replacement therapy; 2significant compared to pre-operative status p=0.04; 
3significant compared to pre-operative status p=0.015; 4significant compared to pre-operative status p=0.01; 
 
 
- Pancreatic atrophy, % 60 (22.5-70) 
Pancreatic Calcification 17 (94%) 
- Head 17 (94%) 
- Neck 16 (88%) 
- Body 14 (78%) 
- Tail 13 (72%) 
Pancreatic duct dilatation/stricture 12 (67%) 
Fluid collection 11 (61%) 
Pseudocysts 10 (56%) 
Inflammatory head mass 8 (44%) 
Biliary obstruction 5 (28%) 
Gastric outlet obstruction 5 (28%) 
Pancreato-peritoneal fistula 1 (6%) 
Operative details  
Operation duration:  median (IQR) 6h 37m (5h 17m – 7h 10m) 
Overall blood transfusion, units:  median (IQR) 0 (0-3) 
Patients blood transfused 8 (44%) 
Median blood transfusion in the 8 transfused 3 (1.25-5.75) 
Splenectomy performed 4(22%) 
Post-operative complications (Clavien-Dindo)  
Any Complication 9 (50%) 
I 2 (11%) 
II 5 (28%) 
IIIa/b 1 (6%) 
IVa/b 1 (6%) 
V 0 (0%) 
Hospital Stay: days, median (IQR) 13.5 (10-21.3) 
Follow-up  
Length of follow-up, months:  median (IQR) 32.5 (21-45.8)  
Diabetes mellitus 217 (94%) 
Pancreatic exocrine insufficiency 18 (100%) 
1PERT, lipase units 3325,000 (242,500 – 450,000) 
Post-op employment status: Employed 413 (67%) 
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